Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...
PureTech Health (PRTC) noted that its founded entity, Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia ...
Biosciences' lead drug candidate, VE303, has been reported to demonstrate efficacy in preventing recurrent Clostridioides ...
11d
Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026 ...
Neurocrine Biosciences, Inc. today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device. In this role, Dr. Ratz will lead the ...
CAMBRIDGE, Mass., January 23, 2025--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the ...
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results ...
VE-303 is under clinical development by Vedanta Biosciences and currently in Phase III for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback